Version 2.76

Term Description

Qualitative results for SARS Coronavirus 2 (SARS-CoV-2) virus neutralizing antibodies in serum by pVNT (pseudovirus neutralization test). Neutralizing antibody testing is performed to determine whether the antibodies produced after SARS-CoV-2 infection or in response to a vaccination are able to neutralize the virus and prevent infection or re-infection. Different methods can be used to determine the presence of neutralizing antibodies, including VNT (virus neutralization test) and pVNT, which are represented in LOINC as the Method "Neutralization" and "pVNT", respectively. The pVNT method for SARS-CoV-2 neutralizing antibody testing uses recombinant pseudoviruses that incorporate the S protein from SARS-CoV-2, whereas VNT uses SARS-CoV-2 virus from a clinical isolate or recombinant SARS-CoV-2 expressing reporter proteins.
Source: Regenstrief LOINC

Part Descriptions

LP207365-0   Ab.Neut
Neutralizing antibodies are antibodies that interfere with the interaction between the virus and its host cell receptor, therefore preventing infectivity. Neutralizing antibodies can be detected using a traditional VNT or other methods such as pseudovirus VNT and surrogate VNT. VNT and pseudovirus VNT use live virus (the actual virus or a recombinant virus that incorporates the viral antigen of interest, respectively) and cell culture to assess the virus-host interaction and whether neutralizing antibodies are present that block that interaction. Surrogate VNT (sVNT) does not use live virus but rather uses purified viral antigen and host cell receptor protein to mimic the same interaction. The sVNT method is currently (2021) represented in LOINC as IA, because it is an immunoassay-based method. Source: Regenstrief LOINC

LP417540-4   SARS coronavirus 2
The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.

The full genome of the 2019-nCoV was first posted by Chinese health authorities in GenBank, the NIH genetic sequence database, and in the Global Initiative on Sharing All Influenza Data (GISAI) portal. This facilitated detection of the virus globally with subsequent sequences being nearly identical, suggesting a single, recent emergence from a virus related to bat coronaviruses and the SARS coronavirus. Source: LOINC

LP419175-7   pVNT
The pseudovirus neutralization test (pVNT) is similar to the conventional VNT; both are laboratory methods that are used primarily for identifying whether neutralizing antibodies for the virus of interest are present in the patient sample. The VNT involves incubating patient serum with the virus of interest, and then inoculating onto cell culture. If neutralizing antibodies are present and the virus is neutralized, the cells will not be infected. If neutralizing antibodies are not present, the virus will infect the cells in the cell culture. In the pVNT, a recombinant virus that incorporates the viral antigen of interest is used rather than the virus of interest itself. PMID: 32170698 Source: Regenstrief LOINC

Reference Information

Type Source Reference
Webcontent Lab Tests Online®Copyright Copyright © 2021 Lab Tests Online. All rights reserved. Coronavirus (COVID-19) Testing

Fully-Specified Name

SARS coronavirus 2 Ab.neut

Additional Names

Short Name
SARS-CoV-2 NAb Ser Ql pVNT
Display Name
SARS-CoV-2 (COVID-19) neut ab pVNT Ql (S)
Consumer Name Alpha Get Info
SARS-CoV-2 (COVID-19) neutralizing antibody, Blood

Ask at Order Entry

81959-9 Public health laboratory ask at order entry panel

This panel contains a convenience grouping of terms for questions commonly asked when an order is placed in a public health laboratory.

LOINC Name R/O/C Cardinality Example UCUM Units
81959-9 Public health laboratory ask at order entry panel
Indent81744-5 Submitter's laboratory test method [Type] in Specimen
Indent81658-7 Suspected organism [Identifier] in Specimen
Indent86952-9 Preliminary testing done Specimen
Indent86953-7 Preliminary testing result Specimen
Indent86955-2 Preliminary testing affected submission for further testing Specimen
Indent95417-2 Whether this is the patient's first test for condition of interest
Indent95418-0 Whether patient is employed in a healthcare setting
Indent95419-8 Whether the patient has symptoms related to condition of interest
Indent11368-8 Illness or injury onset date and time C
Indent77974-4 Whether the patient was hospitalized for condition of interest
Indent95420-6 Whether the patient was admitted to intensive care unit (ICU) for condition of interest
Indent95421-4 Whether patient resides in a congregate care setting
Indent82810-3 Pregnancy status C
Indent30525-0 Age a

Example Answer List: LL2009-0

Source: ARUP Laboratories
Answer Code Score Answer ID
PositiveCopyright ID:10828004 Positive (qualifier value) LA6576-8
NegativeCopyright ID:260385009 Negative (qualifier value) LA6577-6
EquivocalCopyright ID:42425007 Equivocal (qualifier value) LA11885-3

Basic Attributes

First Released
Version 2.68
Last Updated
Version 2.69
Order vs. Observation

Member of these Groups Get Info

LOINC Group Group Name
LG51018-6 SARSCoV2 antibody detection

Language Variants Get Info

Tag Language Translation
de-DE German (Germany) SARS-Coronavirus 2 Ak.neutralisierend:Nachweis oder Schwellenwert:Zeitpunkt:Serum:Ordinal:Pseudovirus-Neutralisationstest
es-ES Spanish (Spain) Panel del SARS-CoV-2 (COVID-19) Anticuerpos antineutrófilos:PrThr:Punto temporal:Suero:Ord:Prueba de neutralización de pseudovirus (pVNT)
es-MX Spanish (Mexico) SARS coronavirus 2 Ab.neut:Presencia o umbral:Punto temporal:Suero:Ordinal:Prueba de neutralización de pseudovirus (pVNT)
fr-FR French (France) Coronavirus SARS-CoV-2 Ac neutralisant:Présence/Seuil:Ponctuel:Sérum:Qualitatif:Test de neutralisation pseudovirus (pVNT)
it-IT Italian (Italy) SARS coronavirus 2 Ab.Neut:PrThr:Pt:Siero:Ord:pVNT
Synonyms: anticorpo Coronavirus della SARS Microbiologia Presenza o Soglia Punto nel tempo (episodio) SARS-CoV-2 (COVID-19) Siero
nl-NL Dutch (Netherlands) SARS-CoV-2 As.neutraliserend:aanwezigheid:moment:serum:ordinaal:pseudovirus-neutralisatietest
Synonyms: antistof; antilichaam pVNT SARS-virus severe acute respiratory syndrome coronavirus 2; 2019-nCoV; 2019 novel coronavirus; COVID-19
zh-CN Chinese (China) SARS 冠状病毒 2 抗体.中和:存在情况或阈值:时间点:血清:序数型:假病毒中和试验
Synonyms: 2019 新型冠状病毒;2019 年新型冠状病毒;2019-nCoV;SARS-CoV-2;新型冠状病毒肺炎;新冠肺炎;Coronavirus disease 2019;COVID-19;冠状病毒疾病2019;严重急性呼吸综合征;severe acute respiratory syndrome;SARS;传染性非典型肺炎;infectious atypical pneumonia;非典 Ⅱ Ab;自身抗体 II SARS;SARS 病毒;SARS-CoV;严重急性呼吸综合征;严重急性呼吸综合征病毒;萨斯病毒;非典;非典型肺炎;非典型肺炎病毒;非典病毒 中和试验;中和抗体;中和 伪病中和试验;基于伪病毒的病毒中和试验;基于伪病毒的病毒中和测试;Pseudovirus neutralization test;pVNT;假病毒体外中和试验;pseudovirus based neutralization assay;PBNA 依次型;分类顺序型;定性的;序数型(或称等级型);性质上的;有序型;有序性分类应答;有序性分类结果;秩次型;等级型;筛查;顺序型 存在情况;存在;存在与否;是否存在;阈值;界值;界限;阀值;临界值;存在情况(存在、存在与否、是否存在)或阈值(界值、界限、阀值、临界值) 微生物学;微生物学试验;微生物学试验(培养、DNA、抗原及抗体) 时刻;随机;随意;瞬间

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup$lookup?system=